ATH-399A by NurrOn Pharmaceuticals for Parkinson's Disease: Likelihood of Approval
ATH-399A is under clinical development by NurrOn Pharmaceuticals and currently in Phase I for Parkinson's Disease.
Source: pharmaceutical-technology.com
Page 5 - Pharmaceutical Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmaceutical Intelligence Today - Breaking & Trending Today
CLN-619 by Cullinan Oncology for Colon Cancer: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Oncology and currently in Phase I for Colon Cancer.
Source: pharmaceutical-technology.com
Ezabenlimab by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.
Source: pharmaceutical-technology.com
KB-0742 by Kronos Bio for Ewing Sarcoma: Likelihood of Approval
KB-0742 is under clinical development by Kronos Bio and currently in Phase II for Ewing Sarcoma.
Source: pharmaceutical-technology.com
Abemaciclib by Eli Lilly and Co for Primary CNS Lymphoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Primary CNS Lymphoma.
Source: pharmaceutical-technology.com